NK Cell Receptors as Tools in Cancer Immunotherapy

Advances in Cancer Research

Volumn 95, Issue , 2006, Pages 249-292

  Sentman, Charles L ^a   Barber, Melissa A ^a   Barber, Amorette ^a   Zhang, Tong ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5E6 ANTIBODY; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER ANTIBODY; CD16 ANTIBODY; CD19 ANTIBODY; CD20 ANTIBODY; CD27 ANTIGEN; CD30 ANTIBODY; CD40 LIGAND; CD56 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CHIMERIC NKG2D; CHIMERIC PROTEIN; COMPLEMENT COMPONENT C1Q; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; LY49 RECEPTOR INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; RECEPTOR BLOCKING AGENT; RITUXIMAB; ULBP2 BB4 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA POLYMORPHISM; GENE EXPRESSION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LEUKEMIA; MOLECULAR RECOGNITION; MYELOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; TIME FACTORS;

EID: 33745988238     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(06)95007-6     Document Type: Review

References (228)

1. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
2. Anderson S.K., Dewar K., Goulet M.L., Leveque G., and Makrigiannis A.P. Complete elucidation of a minimal class I MHC natural killer cell receptor haplotype. Genes Immun. 6 (2005) 481-492
3. Andrews D.M., Scalzo A.A., Yokoyama W.M., Smyth M.J., and Degli-Esposti M.A. Functional interactions between dendritic cells and NK cells during viral infection. Nat. Immunol. 4 (2003) 175-181
4. Arase H., Arase N., and Saito T. Interferon-g production by natural killer (NK) cells and NK 1.1+ T cells upon NKR-P1 cross-linking. J. Exp. Med. 183 (1996) 2391-2396
5. Arase H., Mocarski E.S., Campbell A.E., Hill A.B., and Lanier L.L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296 (2002) 1323-1326
6. Arnon T.I., Lev M., Katz G., Chernobrov Y., Porgador A., and Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. 31 (2001) 2680-2689
7. Bahram S. MIC genes: From genetics to biology. Adv. Immunol. 76 (2000) 1-60
8. Bakker A.B., Phillips J.H., Figdor C.G., and Lanier L.L. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J. Immunol. 160 (1998) 5239-5245
9. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., and Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
10. Bellone G., Valiante N.M., Viale O., Ciccone E., Moretta L., and Trinchieri G. Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones. J. Exp. Med. 177 (1993) 1117-1125
11. Bennett M. Biology and genetics of hybrid resistance. Adv. Immunol. 41 (1987) 333-445
12. Biassoni R., Pessino A., Bottino C., Pende D., Moretta L., and Moretta A. The murine homologue of the human NKp46, a triggering receptor involved in the induction of natural cytotoxicity. Eur. J. Immunol. 29 (1999) 1014-1020
13. Bignon J.D., and Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr. Opin. Immunol. 17 (2005) 553-559
14. Billadeau D.D., Upshaw J.L., Schoon R.A., Dick C.J., and Leibson P.J. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol. 4 (2003) 557-564
15. Biron C.A., and Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13 (2001) 458-464
16. Bishara A., De Santis D., Witt C.C., Brautbar C., Christiansen F.T., Or R., Nagler A., and Slavin S. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63 (2004) 204-211
17. Boles K.S., Stepp S.E., Bennett M., Kumar V., and Mathew P.A. 2B4 (CD244) and CS1: Novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol. Rev. 181 (2001) 234-249
18. Borrego F., Ulbrecht M., Weiss E.H., Coligan J.E., and Brooks A.G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187 (1998) 813-818
19. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., Cantoni C., Grassi J., Marcenaro S., Reymond N., Vitale M., Moretta L., et al. Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198 (2003) 557-567
20. Bottino C., Castriconi R., Moretta L., and Moretta A. Cellular ligands of activating NK receptors. Trends Immunol. 26 (2005) 221-226
21. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., Lazetic S., Young N.T., Bell J.I., Phillips J.H., Lanier L.L., and McMichael A.J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998) 795-799
22. Brennan J., Mahon G., Mager D.L., Jefferies W.A., and Takei F. Recognition of class I major histocompatibility complex molecules by Ly-49: Specificities and domain interactions. J. Exp. Med. 183 (1996) 1553-1559
23. Brown M.H., Boles K., van der Merwe P.A., Kumar V., Mathew P.A., and Barclay A.N. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J. Exp. Med. 188 (1998) 2083-2090
24. Bruenke J., Barbin K., Kunert S., Lang P., Pfeiffer M., Stieglmaier K., Niethammer D., Stockmeyer B., Peipp M., Repp R., Valerius T., and Fey G.H. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br. J. Haematol. 130 (2005) 218-228
25. Butcher S., Arney K.L., and Cook G.P. MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells. Eur. J. Immunol. 28 (1998) 3755-3762
26. Carayannopoulos L.N., Naidenko O.V., Fremont D.H., and Yokoyama W.M. Cutting edge: Murine UL16-binding protein-like transcript 1: A newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169 (2002) 4079-4083
27. Carbone E., Ruggiero G., Terrazzano G., Palomba C., Manzo C., Fontana S., Spits H., Kärre K., and Zappacosta S. A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction. J. Exp. Med. 185 (1997) 2053-2060
28. Carbone E., Neri P., Mesuraca M., Fulciniti M.T., Otsuki T., Pende D., Groh V., Spies T., Pollio G., Cosman D., Catalano L., Tassone P., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105 (2005) 251-258
29. Carlyle J.R., Martin A., Mehra A., Attisano L., Tsui F.W., and Zuniga-Pflucker J.C. Mouse NKR-P1B, a novel NK1.1 antigen with inhibitory function. J. Immunol. 162 (1999) 5917-5923
30. Carlyle J.R., Jamieson A.M., Gasser S., Clingan C.S., Arase H., and Raulet D.H. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc. Natl. Acad. Sci. USA 101 (2004) 3527-3532
31. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
32. Castriconi R., Cantoni C., Della Chiesa M., Vitale M., Marcenaro E., Conte R., Biassoni R., Bottino C., Moretta L., and Moretta A. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100 (2003) 4120-4125
33. Cella M., Longo A., Ferrara G.B., Strominger J.L., and Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J. Exp. Med. 180 (1994) 1235-1242
34. Cerwenka A., and Lanier L.L. Ligands for natural killer cell receptors: Redundancy or specificity. Immunol. Rev. 181 (2001) 158-169
35. Cerwenka A., and Lanier L.L. NKG2D ligands: Unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61 (2003) 335-343
36. Cerwenka A., Baron J.L., and Lanier L.L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98 (2001) 11521-11526
37. Chalifour A., Jeannin P., Gauchat J.F., Blaecke A., Malissard M., N'Guyen T., Thieblemont N., and Delneste Y. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 104 (2004) 1778-1783
38. Chambers B.J., Salcedo M., and Ljunggren H.G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5 (1996) 311-317
39. Chan A.T., Kollnberger S.D., Wedderburn L.R., and Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 52 (2005) 3586-3595
40. Chang C.C., Campoli M., and Ferrone S. Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: Current challenges and future directions. Adv. Cancer Res. 93 (2005) 189-234
41. Coles M.C., McMahon C.W., Takizawa H., and Raulet D.H. Memory CD8 T lymphocytes express inhibitory MHC-specific Ly49 receptors. Eur. J. Immunol. 30 (2000) 236-244
42. Colonna M., Borsellino G., Falco M., Ferrara G.B., and Strominger J.L. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. USA 90 (1993) 12000-12004
43. Conejo-Garcia J.R., Benencia F., Courreges M.C., Khang E., Zhang L., Mohamed-Hadley A., Vinocur J.M., Buckanovich R.J., Thompson C.B., Levine B., and Coukos G. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol. Ther. 2 (2003) 446-451
44. Conejo-Garcia J.R., Benencia F., Courreges M.C., Gimotty P.A., Khang E., Buckanovich R.J., Frauwirth K.A., Zhang L., Katsaros D., Thompson C.B., Levine B., and Coukos G. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res. 64 (2004) 2175-2182
45. Corral L., Hanke T., Vance R.E., Cado D., and Raulet D.H. NK cell expression of the killer cell lectin-like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules. Eur. J. Immunol. 30 (2000) 920-930
46. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., Kubin M., and Chalupny N.J. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14 (2001) 123-133
47. Crocker P.R., and Varki A. Siglecs in the immune system. Immunology 103 (2001) 137-145
48. Daniels K.A., Devora G., Lai W.C., O'Donnell C.L., Bennett M., and Welsh R.M. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J. Exp. Med. 194 (2001) 29-44
49. Davies S.M., Ruggieri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., Velardi A., and Blazar B.R. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 (2002) 3825-3827
50. Degli-Esposti M.A., and Smyth M.J. Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5 (2005) 112-124
51. Demanet C., Mulder A., Deneys V., Worsham M.J., Maes P., Claas F.H., and Ferrone S. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: An escape mechanism from CTL and NK attack?. Blood 103 (2004) 3122-3130
52. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., and Raulet D.H. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1 (2000) 119-126
53. Diefenbach A., Jensen E.R., Jamieson A.M., and Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001) 165-171
54. Diefenbach A., Tomasello E., Lucas M., Jamieson A.M., Hsia J.K., Vivier E., and Raulet D.H. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3 (2002) 1142-1149
55. Diefenbach A., Hsia J.K., Hsiung M.Y., and Raulet D.H. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur. J. Immunol. 33 (2003) 381-391
56. Dohring C., Scheidegger D., Samaridis J., Cella M., and Colonna M. A human killer inhibitory receptor specific for HLA-A. J. Immunol. 156 (1996) 3098-3101
57. Dokun A.O., Kim S., Smith H.R., Kang H.S., Chu D.T., and Yokoyama W.M. Specific and nonspecific NK cell activation during virus infection. Nat. Immunol. 2 (2001) 951-956
58. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3 (2003) 666-675
59. Ehrlich L.I., Ogasawara K., Hamerman J.A., Takaki R., Zingoni A., Allison J.P., and Lanier L.L. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J. Immunol. 174 (2005) 1922-1931
60. Fahlen L., Oberg L., Brannstrom T., Khoo N.K., Lendahl U., and Sentman C.L. Ly49A expression on T cells alters T cell selection. Int. Immunol. 12 (2000) 215-222
61. Falco M., Biassoni R., Bottino C., Vitale M., Sivori S., Augugliaro R., Moretta L., and Moretta A. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J. Exp. Med. 190 (1999) 793-802
62. Ferlazzo G., Tsang M.L., Moretta L., Melioli G., Steinman R.M., and Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195 (2002) 343-351
63. Flores-Villanueva P.O., Yunis E.J., Delgado J.C., Vittinghoff E., Buchbinder S., Leung J.Y., Uglialoro A.M., Clavijo O.P., Rosenberg E.S., Kalams S.A., Braun J.D., Boswell, et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. USA 98 (2001) 5140-5145
64. Garni-Wagner B.A., Purohit A., Mathew P.A., Bennett M., and Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J. Immunol. 151 (1993) 60-70
65. Gasser S., Orsulic S., Brown E.J., and Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005) 1186-1190
66. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S.E., Theoret M.R., Rosenberg S.A., and Restifo N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115 (2005) 1616-1626
67. Geldhof A.B., Moser M., Lespagnard L., Thielemans K., and De Baetselier P. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91 (1998) 196-206
68. George T.C., Mason L.H., Ortaldo J.R., Kumar V., and Bennett M. Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells. J. Immunol. 162 (1999) 2035-2043
69. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., Maccario R., Bonetti F., Wojnar J., Martinetti M., Frassoni F., Giorgiani G., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
70. Giebel S., Locatelli F., Wojnar J., Velardi A., Mina T., Giorgiani G., Krawczyk-Kulis M., Markiewicz M., Wylezol I., and Holowiecki J. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br. J. Haematol. 131 (2005) 483-486
71. Gilfillan S., Ho E.L., Cella M., Yokoyama W.M., and Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3 (2002) 1150-1155
72. Glas R., Franksson L., Une C., Eloranta M.L., Ohlen C., Orn A., and Kärre K. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J. Exp. Med. 191 (2000) 129-138
73. Groh V., Bahram S., Bauer S., Herman A., Beauchamp M., and Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93 (1996) 12445-12450
74. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96 (1999) 6879-6884
75. Groh V., Rhinehart R., Randolph-Habecker J., Topp M.S., Riddell S.R., and Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2 (2001) 255-260
76. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
77. Groh V., Bruhl A., El-Gabalawy H., Nelson J.L., and Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100 (2003) 9452-9457
78. Grundemann C., Bauer M., Schweier O., von Oppen N., Lassing U., Saudan P., Becker K.F., Karp K., Hanke T., Bachmann M.F., and Pircher H. Cutting edge: Identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J. Immunol. 176 (2006) 1311-1315
79. Hansasuta P., Dong T., Thananchai H., Weekes M., Willberg C., Aldemir H., Rowland-Jones S., and Braud V.M. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34 (2004) 1673-1679
80. Hartmann F., Renner C., Jung W., da Costa L., Tembrink S., Held G., Sek A., Konig J., Bauer S., Kloft M., and Pfreundschuh M. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines. Clin. Cancer Res. 7 (2001) 1873-1881
81. Hayakawa Y., Kelly J.M., Westwood J.A., Darcy P.K., Diefenbach A., Raulet D., and Smyth M.J. Cutting edge: Tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. Immunol. 169 (2002) 5377-5381
82. Held W., and Raulet D.H. Ly49A transgenic mice provide evidence for a major histocompatibility complex-dependent education process in natural killer cell development. J. Exp. Med. 185 (1997) 2079-2088
83. Herberman R.B., Nunn M.E., Holden H.T., and Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16 (1975) 230-239
84. Herberman R.B., Nunn M.E., and Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 16 (1975) 216-229
85. Hiby S.E., Walker J.J., O'Shaughnessy K.M., Redman C.W., Carrington M., Trowsdale J., and Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200 (2004) 957-965
86. Hintzen R.Q., de Jong R., Lens S.M., and van Lier R.A. CD27: Marker and mediator of T-cell activation?. Immunol. Today 15 (1994) 307-311
87. Hoglund P., Ljunggren H.G., Ohlen C., Ahrlund-Richter L., Scangos G., Bieberich C., Jay G., Klein G., and Kärre K. Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J. Exp. Med. 168 (1988) 1469-1474
88. Holdenrieder S., Stieber P., Peterfi A., Nagel D., Steinle A., and Salih H.R. Soluble MICA in malignant diseases. Int. J. Cancer 118 (2006) 684-687
89. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., and Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168 (2002) 4531-4537
90. Houchins J.P., Yabe T., McSherry C., and Bach F.H. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J. Exp. Med. 173 (1991) 1017-1020
91. Hsu K.C., Liu X.R., Selvakumar A., Mickelson E., O'Reilly R.J., and Dupont B. Killer Ig-like receptor haplotype analysis by gene content: Evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J. Immunol. 169 (2002) 5118-5129
92. Hsu K.C., Keever-Taylor C.A., Wilton A., Pinto C., Heller G., Arkun K., O'Reilly R.J., Horowitz M.M., and Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
93. Hue S., Mention J.J., Monteiro R.C., Zhang S., Cellier C., Schmitz J., Verkarre V., Fodil N., Bahram S., Cerf-Bensussan N., and Caillat-Zucman S. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21 (2004) 367-377
94. Idris A.H., Smith H.R., Mason L.H., Ortaldo J.R., Scalzo A.A., and Yokoyama W.M. The natural killer gene complex genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing. Proc. Natl. Acad. Sci. USA 96 (1999) 6330-6335
95. Igarashi T., Wynberg J., Srinivasan R., Becknell B., McCoy Jr. J.P., Takahashi Y., Suffredini D.A., Linehan W.M., Caligiuri M.A., and Childs R.W. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104 (2004) 170-177
96. Iizuka K., Naidenko O.V., Plougastel B.F., Fremont D.H., and Yokoyama W.M. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat. Immunol. 4 (2003) 801-807
97. Ito A., Handa K., Withers D.A., Satoh M., and Hakomori S. Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: Possible role of disialogangliosides in tumor progression. FEBS Lett. 504 (2001) 82-86
98. Ito M., Maruyama T., Saito N., Koganei S., Yamamoto K., and Matsumoto N. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J. Exp. Med. 203 (2006) 289-295
99. Jamieson A.M., Diefenbach A., McMahon C.W., Xiong N., Carlyle J.R., and Raulet D.H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17 (2002) 19-29
100. Jinushi M., Takehara T., Tatsumi T., Kanto T., Groh V., Spies T., Kimura R., Miyagi T., Mochizuki K., Sasaki Y., and Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer 104 (2003) 354-361
101. Jonges L.E., Albertsson P., van Vlierberghe R.L., Ensink N.G., Johansson B.R., van de Velde C.J., Fleuren G.J., Nannmark U., and Kuppen P.J. The phenotypic heterogeneity of human natural killer cells: Presence of at least 48 different subsets in the peripheral blood. Scand. J. Immunol. 53 (2001) 103-110
102. Kane K.P., Lavender K.J., and Ma B.J. Ly-49 receptors and their functions. Crit. Rev. Immunol. 24 (2004) 321-348
103. Karlhofer F.M., Ribaudo R.K., and Yokoyama W.M. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358 (1992) 66-70
104. Karlhofer F.M., Hunziker R., Reichlin A., Margulies D.H., and Yokoyama W.M. Host MHC class I molecules modulate in vivo expression of a NK cell receptor. J. Immunol. 153 (1994) 2407-2416
105. Kärre K., Ljunggren H.G., Piontek G., and Kiessling. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature 319 (1986) 675-678
106. Katz G., Markel G., Mizrahi S., Arnon T.I., and Mandelboim O. Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4. J. Immunol. 166 (2001) 7260-7267
107. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., and Smyth M.J. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3 (2002) 83-90
108. Kelly J.M., Takeda K., Darcy P.K., Yagita H., and Smyth M.J. A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J. Immunol. 168 (2002) 4472-4479
109. Kiessling R., Klein E., Pross H., and Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol. 5 (1975) 117-121
110. Kiessling R., Klein E., and Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5 (1975) 112-117
111. Koh C.Y., Blazar B.R., George T., Welniak L.A., Capitini C.M., Raziuddin A., Murphy W.J., and Bennett M. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97 (2001) 3132-3137
112. Koh C.Y., Raziuddin A., Welniak L.A., Blazar B.R., Bennett M., and Murphy W.J. NK inhibitory-receptor blockade for purging of leukemia: Effects on hematopoietic reconstitution. Biol. Blood Marrow Transplant. 8 (2002) 17-25
113. Koh C.Y., Ortaldo J.R., Blazar B.R., Bennett M., and Murphy W.J. NK-cell purging of leukemia: Superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood 102 (2003) 4067-4075
114. Koo G.C., and Peppard J.R. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 3 (1984) 301-303
115. Kubota K. A structurally variant form of the 2B4 antigen is expressed on the cell surface of mouse mast cells. Microbiol. Immunol. 46 (2002) 589-592
116. Kumar V., and McNerney M.E. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat. Rev. Immunol. 5 (2005) 363-374
117. Kung S.K., Su R.C., Shannon J., and Miller R.G. The NKR-P1B gene product is an inhibitory receptor on SJL/J NK cells. J. Immunol. 162 (1999) 5876-5887
118. Lanier L.L. NK cell receptors. Annu. Rev. Immunol. 16 (1998) 359-393
119. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 23 (2005) 225-274
120. Lanier L.L., Chang C., and Phillips J.H. Human NKR-P1A: A disulfide linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J. Immunol. 153 (1994) 2417-2428
121. Lanier L.L., Corliss B.C., Wu J., Leong C., and Phillips J.H. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391 (1998) 703-707
122. Lazetic S., Chang C., Houchins J.P., Lanier L.L., and Phillips J.H. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J. Immunol. 157 (1996) 4741-4745
123. Lee J.C., Lee K.M., Kim D.W., and Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172 (2004) 7335-7340
124. Lee K.M., McNerney M.E., Stepp S.E., Mathew P.A., Schatzle J.D., Bennett M., and Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J. Exp. Med. 199 (2004) 1245-1254
125. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., Niethammer D., and Handgretinger R. Determinants of antileukemia effects of allogeneic NK cells. J. Immunol. 172 (2004) 644-650
126. Litwin V., Gumperz J., Parham P., Phillips J.H., and Lanier L.L. NKB1: A natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J. Exp. Med. 180 (1994) 537-543
127. Ljunggren H.G., and Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11 (1990) 237-244
128. Maasho K., Opoku-Anane J., Marusina A.I., Coligan J.E., and Borrego F. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J. Immunol. 174 (2005) 4480-4484
129. Maccalli C., Pende D., Castelli C., Mingari M.C., Robbins P.F., and Parmiani G. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur. J. Immunol. 33 (2003) 2033-2043
130. Makrigiannis A.P., and Anderson S.K. Ly49 gene expression in different inbred mouse strains. Immunol. Res. 21 (2000) 39-47
131. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., Davis D.M., Strominger J.L., Yewdell J.W., and Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 22 (2001) 1055-1060
132. Markel G., Lieberman N., Katz G., Arnon T.I., Lotem M., Drize O., Blumberg R.S., Bar-Haim E., Mader R., Eisenbach L., and Mandelboim O. CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. J. Immunol. 168 (2002) 2803-2810
133. Markiewicz M.A., Carayannopoulos L.N., Naidenko O.V., Matsui K., Burack W.R., Wise E.L., Fremont D.H., Allen P.M., Yokoyama W.M., Colonna M., and Shaw A.S. Costimulation through NKG2D enhances murine CD8+ CTL function: Similarities and differences between NKG2D and CD28 costimulation. J. Immunol. 175 (2005) 2825-2833
134. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., Wilson M., O'Brien S.J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31 (2002) 429-434
135. Martin-Pagola A., Perez-Nanclares G., Ortiz L., Vitoria J.C., Hualde I., Zaballa R., Preciado E., Castano L., and Bilbao J.R. MICA response to gliadin in intestinal mucosa from celiac patients. Immunogenetics 56 (2004) 549-554
136. Mason L.H., Ortaldo J.R., Young H.A., Kumar V., Bennett M., and Anderson S.K. Cloning and functional characteristics of murine large granular lymphocyte-1: A member of the Ly-49 gene family (Ly-49G2). J. Exp. Med. 182 (1995) 293-303
137. Mason L.H., Willette-Brown J., Mason A.T., McVicar D., and Ortaldo J.R. Interaction of Ly-49D+ NK cells with H-2Dd target cells leads to Dap-12 phosphorylation and IFN-g secretion. J. Immunol. 164 (2000) 603-611
138. McNerney M.E., Lee K.M., and Kumar V. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Mol. Immunol. 42 (2005) 489-494
139. Meresse B., Chen Z., Ciszewski C., Tretiakova M., Bhagat G., Krausz T.N., Raulet D.H., Lanier L.L., Groh V., Spies T., Ebert E.C., Green P.H., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21 (2004) 357-366
140. Meyaard L. LAIR-1, a widely distributed human ITIM-bearing receptor on hematopoietic cells. Curr. Top. Microbiol. Immunol. 244 (1999) 151-157
141. Meyaard L., Adema G.J., Chang C., Woollatt E., Sutherland G.R., Lanier L.L., and Phillips J.H. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 7 (1997) 283-290
142. Mocikat R., Braumuller H., Gumy A., Egeter O., Ziegler H., Reusch U., Bubeck A., Louis J., Mailhammer R., Riethmuller G., Koszinowski U., and Rocken M. Natural killer cells activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19 (2003) 561-569
143. Moller M.J., Kammerer R., Grunert F., and von Kleist S. Biliary glycoprotein (BGP) expression on T cells and on a natural-killer-cell sub-population. Int. J. Cancer 65 (1996) 740-745
144. Momot T., Koch S., Hunzelmann N., Krieg T., Ulbricht K., Schmidt R.E., and Witte T. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 50 (2004) 1561-1565
145. Moretta L., and Moretta A. Killer immunoglobulin-like receptors. Curr. Opin. Immunol. 16 (2004) 626-633
146. Moretta L., and Moretta A. Unravelling natural killer cell function: Triggering and inhibitory human NK receptors. EMBO J. 23 (2004) 255-259
147. + natural killer cells: Role in cell activation and regulation of cytolytic function. J. Exp. Med. 171 (1990) 695-714
148. + natural killer (NK) cells by the expression of clonally distributed functional surface molecules: Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J. Exp. Med. 172 (1990) 1589-1598
149. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., Biassoni R., and Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19 (2001) 197-223
150. Munitz A., Bachelet I., Fraenkel S., Katz G., Mandelboim O., Simon H.U., Moretta L., Colonna M., and Levi-Schaffer F. 2B4 (CD244) is expressed and functional on human eosinophils. J. Immunol. 174 (2005) 110-118
151. Nakamura M.C., Naper C., Niemi E.C., Spusta S.C., Rolstad B., Butcher G.W., Seaman W.E., and Ryan J.C. Natural killing of xenogeneic cells mediated by the mouse Ly-49D receptor. J. Immunol. 163 (1999) 4694-4700
152. Nelson G.W., Martin M.P., Gladman D., Wade J., Trowsdale J., and Carrington M. Cutting edge: Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 173 (2004) 4273-4276
153. Nicoll G., Ni J., Liu D., Klenerman P., Munday J., Dubock S., Mattei M.G., and Crocker P.R. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274 (1999) 34089-34095
154. Oberg L., Eriksson M., Fahlen L., and Sentman C.L. Expression of Ly49A on T cells alters the threshold for T cell responses. Eur. J. Immunol. 30 (2000) 2849-2856
155. O'Callaghan C.A., and Bell J.I. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol. Rev. 163 (1998) 129-138
156. Ogasawara K., Hamerman J.A., Ehrlich L.R., Bour-Jordan H., Santamaria P., Bluestone J.A., and Lanier L.L. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20 (2004) 757-767
157. Olcese L., Cambiaggi A., Semenzato G., Bottino C., Moretta A., and Vivier E. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J. Immunol. 158 (1997) 5083-5086
158. Olsson M.Y., Kärre K., and Sentman C.L. Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand. Proc. Natl. Acad. Sci. USA 92 (1995) 1649-1653
159. Olsson-Alheim M.Y., Salcedo M., Ljunggren H.G., Kärre K., and Sentman C.L. NK cell receptor calibration: Effects of MHC class I induction on killing by Ly49Ahigh and Ly49Alow NK cells. J. Immunol. 159 (1997) 3189-3194
160. Olsson-Alheim M.Y., Sundback J., Kärre K., and Sentman C.L. The MHC class I molecule H-2Dp inhibits murine NK cells via the inhibitory receptor Ly49A. J. Immunol. 162 (1999) 7010-7014
161. Olszewski A.J., and Grossbard M.L. Empowering targeted therapy: Lessons from rituximab. Sci STKE 241 (2004) 30
162. Oppenheim D.E., Roberts S.J., Clarke S.L., Filler R., Lewis J.M., Tigelaar R.E., Girardi M., and Hayday A.C. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6 (2005) 928-937
163. Ortaldo J.R., and Young H.A. Expression of IFN-gamma upon triggering of activating Ly49D NK receptors in vitro and in vivo: Costimulation with IL-12 or IL-18 overrides inhibitory receptors. J. Immunol. 170 (2003) 1763-1769
164. Pende D., Parolini S., Pessino A., Sivori S., Augugliaro R., Morelli L., Marcenaro E., Accame L., Malaspina A., Biassoni R., Bottino C., Moretta L., et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190 (1999) 1505-1516
165. Pende D., Cantoni C., Rivera P., Vitale M., Castriconi R., Marcenaro S., Nanni M., Biassoni R., Bottino C., Moretta A., and Moretta L. Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur. J. Immunol. 31 (2001) 1076-1086
166. Pende D., Rivera P., Marcenaro S., Chang C.C., Biassoni R., Conte R., Kubin M., Cosman D., Ferrone S., Moretta L., and Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62 (2002) 6178-6186
167. Perussia B., Tutt M.M., Oiu W.O., Kuziel W.A., Tucker P.W., Trinchieri G., Bennett M., Rayetch J.V., and Kumar V. Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene. J. Exp. Med. 170 (1989) 73-86
168. Plougastel B., Dubbelde C., and Yokoyama W.M. Cloning of Clr, a new family of lectin-like genes localized between mouse Nkrp1a and Cd69. Immunogenetics 53 (2001) 209-214
169. Pogge von Strandmann E., Hansen H.P., Reiners K.S., Schnell R., Borchmann P., Merkert S., Simhadri V.R., Draube A., Reiser M., Purr I., Hallek M., and Engert A. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107 (2005) 1955-1962
170. Rajagopalan S., and Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189 (1999) 1093-1099
171. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3 (2003) 781-790
172. Raulet D.H. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat. Immunol. 5 (2004) 996-1002
173. Raulet D.H., Vance R.E., and McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19 (2001) 291-330
174. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 19 (2001) 275-290
175. Robbins S.H., Nguyen K.B., Takahashi N., Mikayama T., Biron C.A., and Brossay L. Cutting edge: Inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J. Immunol. 168 (2002) 2585-2589
176. Robbins S.H., Tessmer M.S., Mikayama T., and Brossay L. Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection. J. Immunol. 173 (2004) 259-266
177. Rolstad B., Naper C., Lovik G., Vaage J.T., Ryan J.C., Backman-Petersson E., Kirsch R.D., and Butcher G.W. Rat natural killer cell receptor systems and recognition of MHC class I molecules. Immunol. Rev. 181 (2001) 149-157
178. Rosen D.B., Araki M., Hamerman J.A., Chen T., Yamamura T., and Lanier L.L. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173 (2004) 2470-2478
179. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., and White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86 (1994) 1159-1166
180. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M.F., and Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
181. Ruggeri L., Mancusi A., Capanni M., Martelli M.F., and Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr. Opin. Immunol. 17 (2005) 211-217
182. Ryan J.C., Niemi E.C., Nakamura M.C., and Seaman W.E. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J. Exp. Med. 181 (1995) 1911-1915
183. Salih H.R., Antropius H., Gieseke F., Lutz S.Z., Kanz L., Rammensee H.G., and Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102 (2003) 1389-1396
184. Schaffer M., Malmberg K.J., Ringden O., Ljunggren H.G., and Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 78 (2004) 1081-1085
185. Schatzle J.D., Sheu S., Stepp S.E., Mathew P.A., Bennett M., and Kumar V. Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc. Natl. Acad. Sci. USA 96 (1999) 3870-3875
186. Schlenzka J., Moehler T.M., Kipriyanov S.M., Kornacker M., Benner A., Bahre A., Stassar M.J., Schafer H.J., Little M., Goldschmidt H., and Cochlovius B. Combined effect of recombinant CD19 × CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drugs 15 (2004) 915-919
187. Schmidt K.N., Leung B., Kwong M., Zarember K.A., Satyal S., Navas T.A., Wang F., and Godowski P.J. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J. Immunol. 172 (2004) 138-143
188. Shahied L.S., Tang Y., Alpaugh R.K., Somer R., Greenspon D., and Weiner L.M. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279 (2004) 53907-53914
189. Shibuya A., Campbell D., Hannum C., Yssel H., Franz-Bacon K., McClanahan T., Kitamura T., Nicholl J., Sutherland G.R., Lanier L.L., and Phillips J.H. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T-lymphocytes. Immunity 4 (1996) 573-581
190. Sivori S., Vitale M., Morelli L., Sanseverino L., Augugliaro R., Bottino C., Moretta L., and Moretta A. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J. Exp. Med. 186 (1997) 1129-1136
191. Sivori S., Falco M., Della Chiesa M., Carlomagno S., Vitale M., Moretta L., and Moretta A. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA 101 (2004) 10116-10121
192. Smith K.M., Wu J., Bakker A.B.H., Phillips J.H., and Lanier L.L. Cutting Edge: Ly49D and Ly49H associate with mouse DAP12 and form activating receptors. J. Immunol. 161 (1998) 7-10
193. Smith H.R., Heusel J.W., Mehta I.K., Kim S., Dorner B.G., Naidenko O.V., Iizuka K., Furukawa H., Beckman D.L., Pingel J.T., Scalzo A.A., Fremont D.H., et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. USA 99 (2002) 8826-8831
194. Smyth M.J., Hayakawa Y., Takeda K., and Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2 (2002) 850-861
195. Sutherland C.L., Chalupny N.J., Schooley K., VandenBos T., Kubin M., and Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168 (2002) 671-679
196. Tajima K., Matsumoto N., Ohmori K., Wada H., Ito M., Suzuki K., and Yamamoto K. Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers. Int. Immunol. 16 (2004) 385-393
197. Takeda K., Oshima H., Hayakawa Y., Akiba H., Atsuta M., Kobata T., Kobayashi K., Ito M., Yagita H., and Okumura K. CD27-mediated activation of murine NK cells. J. Immunol. 164 (2000) 1741-1745
198. Tomasello E., and Vivier E. KARAP/DAP12/TYROBP: Three names and a multiplicity of biological functions. Eur. J. Immunol. 35 (2005) 1670-1677
199. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47 (1989) 187-376
200. Ugolini S., Arpin C., Anfossi N., Walzer T., Cambiaggi A., Forster R., Lipp M., Toes R.E., Melief C.J., Marvel J., and Vivier E. Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat. Immunol. 2 (2001) 430-435
201. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., Tyan D., Lanier L.L., and Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity 7 (1997) 753-763
202. Vaidya S.V., Stepp S.E., McNerney M.E., Lee J.K., Bennett M., Lee K.M., Stewart C.L., Kumar V., and Mathew P.A. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J. Immunol. 174 (2005) 800-807
203. Valiante N.M., and Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Med. 178 (1993) 1397-1406
204. Valiante N.M., Uhrberg M., Shilling H.G., Lienert-Weidenbach K., Arnett K.L., D'Andrea A., Phillips J.H., Lanier L.L., and Parham P. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7 (1997) 739-751
205. Vance R.E., Kraft J.R., Altman J.D., Jensen P.E., and Raulet D.H. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188 (1998) 1841-1848
206. Vance R.E., Jamieson A.M., and Raulet D.H. Recognition of the class Ib molecule Qa-1b by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J. Exp. Med. 190 (1999) 1801-1812
207. Verheyden S., Bernier M., and Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 18 (2004) 2002-2007
208. Verheyden S., Schots R., Duquet W., and Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19 (2005) 1446-1451
209. Verneris M.R., Karami M., Baker J., Jayaswal A., and Negrin R.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103 (2004) 3065-3072
210. Vilches C., and Parham P. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 20 (2002) 217-251
211. Vitale M., Bottino C., Sivori S., Sanseverino L., Castriconi R., Marcenaro E., Augugliaro R., Moretta L., and Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187 (1998) 2065-2072
212. Vivier E., and Anfossi N. Inhibitory NK-cell receptors on T cells: Witness of the past, actors of the future. Nat. Rev. Immunol. 4 (2004) 190-198
213. Vivier E., Morin P., O'Brien C., Druker B., Schlossman S.F., and Anderson P. Tyrosine phosphorylation of the FcgRIII (CD16): ζ Complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J. Immunol. 146 (1991) 206-210
214. Warrington K.J., Takemura S., Goronzy J.J., and Weyand C.M. CD4+, CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum. 44 (2001) 13-20
215. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003) 3940-3947
216. Westwood J.A., Kelly J.M., Tanner J.E., Kershaw M.H., Smyth M.J., and Hayakawa Y. Cutting edge: Novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. J. Immunol. 172 (2004) 757-761
217. Wetzler M., Baer M.R., Stewart S.J., Donohue K., Ford L., Stewart C.C., Repasky E.A., and Ferrone S. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 15 (2001) 128-133
218. Wiemann K., Mittrucker H.W., Feger U., Welte S.A., Yokoyama W.M., Spies T., Rammensee H.G., and Steinle A. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175 (2005) 720-729
219. Wu J., Song Y., Bakker A.B., Bauer S., Spies T., Lanier L.L., and Phillips J.H. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285 (1999) 730-732
220. Wu J.Y., Hill J.M., Ernstoff M.S., and Meehan K.R. The critical role of the NKG2D receptor in CD8+ CTL and CD8+CD56+ NKT cell cytotoxicity. Blood 104 (2004) 865a
221. Yannelli J.R., and Wroblewski J.M. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23 (2004) 97-113
222. Yawata M., Yawata N., Abi-Rached L., and Parham P. Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family. Crit. Rev. Immunol. 22 (2002) 463-482
223. Yokoyama W.M., and Plougastel B.F. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3 (2003) 304-316
224. Yu Y.Y., George T., Dorfman J.R., Roland J., Kumar V., and Bennett M. The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 4 (1996) 67-76
225. Yusa S., Catina T.L., and Campbell K.S. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J. Immunol. 168 (2002) 5047-5057
226. Zhang J.Q., Nicoll G., Jones C., and Crocker P.R. Siglec-9, a novel sialic-acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J. Biol. Chem. 275 (2000) 22121-22126
227. Zhang T., Lemoi B.A., and Sentman C.L. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106 (2005) 1544-1551
228. Zhang T., Barber A., and Sentman C.L. Generation of anti-tumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 106 (2005) (in press)